Improving Glucagon-Like Peptide-1 Dynamics in Patients with Type 2 Diabetes MellitusJournal of the American Osteopathic Association
AbstractThe increased number of cases of type 2 diabetes mellitus (both diagnosed and undiagnosed) parallels the current epidemic of obesity in the United States. Despite receiving treatment, many patients do not achieve established therapeutic goals. Type 2 diabetes mellitus is a progressive disease characterized by multiple abnormalities that extend beyond β-cell dysfunction and insulin resistance. Incretin-based agents, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become important options in the therapeutic paradigm for patients with type 2 diabetes mellitus. The author reviews physiologic mechanisms of the incretin system and discusses the practical application of GLP-1 receptor agonists and DPP-4 inhibitors in improving GLP-1 dynamics in patients with type 2 diabetes mellitus.
Citation InformationJeffrey S. Freeman. "Improving Glucagon-Like Peptide-1 Dynamics in Patients with Type 2 Diabetes Mellitus" Journal of the American Osteopathic Association Vol. 112 Iss. 1 Supplement 1 (2012) p. S2 - S6
Available at: http://works.bepress.com/jeffrey_freeman/9/